Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Capital Leases (2020 - 2025)

Ptc Therapeutics has reported Capital Leases over the past 6 years, most recently at $3.0 million for Q4 2025.

  • Quarterly results put Capital Leases at $3.0 million for Q4 2025, down 80.74% from a year ago — trailing twelve months through Dec 2025 was $3.0 million (down 80.74% YoY), and the annual figure for FY2025 was $3.0 million, down 80.74%.
  • Capital Leases for Q4 2025 was $3.0 million at Ptc Therapeutics, down from $13.8 million in the prior quarter.
  • Over the last five years, Capital Leases for PTCT hit a ceiling of $20.1 million in Q3 2021 and a floor of $3.0 million in Q4 2025.
  • Median Capital Leases over the past 5 years was $17.2 million (2023), compared with a mean of $16.5 million.
  • Biggest five-year swings in Capital Leases: fell 6.75% in 2022 and later tumbled 80.74% in 2025.
  • Ptc Therapeutics' Capital Leases stood at $20.1 million in 2021, then decreased by 7.09% to $18.7 million in 2022, then decreased by 7.98% to $17.2 million in 2023, then decreased by 9.37% to $15.6 million in 2024, then tumbled by 80.74% to $3.0 million in 2025.
  • The last three reported values for Capital Leases were $3.0 million (Q4 2025), $13.8 million (Q3 2025), and $13.8 million (Q2 2025) per Business Quant data.